1.98
+0.02(+1.02%)
Currency In USD
| Previous Close | 1.96 |
| Open | 1.98 |
| Day High | 2.01 |
| Day Low | 1.91 |
| 52-Week High | 3.29 |
| 52-Week Low | 0.13 |
| Volume | 4.19M |
| Average Volume | 18.57M |
| Market Cap | 250.83M |
| PE | -0.14 |
| EPS | -13.68 |
| Moving Average 50 Days | 2.08 |
| Moving Average 200 Days | 1.14 |
| Change | 0.02 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $52.8 as of September 09, 2025 at a share price of $1.98. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 3 years ago, it would be worth $384.47 as of September 09, 2025 at a share price of $1.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growthCAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnol
Vor Bio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 26, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following upcoming investor confere